
Around two years after the AMR Action Fund came into existence with the goal of aiding the development of new antibiotic drugs, the fund has announced its first two investments, a press release reports.
The firms Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals are set to receive undisclosed sums from the fund, which stated its goal to invest USD 1bn in smaller biotech companies when it first set out to fight antimicrobial resistance (AMR) in 2020.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app